Lynk Pharmaceuticals

Lynk Pharmaceuticals expands its partnership with Simcere to commercialize **zemprocitinib**, an oral JAK1 inhibitor developed by Lynk, in dermatology indications across the Chinese Mainland. Simcere gains exclusive rights for distribution and sales in this market, broadening Lynk’s commercial footprint in Asia. The collaboration follows Lynk’s independent development of the second-generation inhibitor.

Nov 2026PR NewswireNews article

Lynk Pharmaceuticals reports positive long-term Phase III trial results for **zemprocitinib**, an oral JAK1 inhibitor, in patients with **moderate-to-severe rheumatoid arthritis** who showed inadequate response to biologic DMARDs. The study evaluates efficacy in this treatment-resistant patient population. Lynk Pharmaceuticals develops therapies for immune and inflammatory diseases.

Oct 2026PR NewswireNews article

Lynk Pharmaceuticals finishes enrolling patients in its Phase III clinical trial of **zemprocitinib** for treating **active ankylosing spondylitis (AS)**. The trial evaluates the drug’s efficacy in this inflammatory condition. This milestone advances development of Lynk’s core product, targeting immune-mediated diseases.

Jul 2026PR NewswireNews article

Formation Bio, a partner of Lynk Pharmaceuticals, begins dosing the first participant in a Phase 1 clinical trial of **BLKR201**, a CNS-penetrant TYK2 inhibitor. The trial marks a key milestone for Lynk’s autoimmune and inflammatory disease pipeline. BLKR201 was previously designated as **LNK01006** under Lynk’s development.

Jun 2026PR NewswireNews article